STILLWATER, Minn., Feb. 17 /PRNewswire/ -- DiaSorin Inc. announced Friday, February 13, that it received Food and Drug Administration clearance for the Company's LIAISON(R) 25-hydroxy Vitamin D and LIAISON(R) N-TACT(TM) PTH Assays. The Company will begin immediate placement of its LIAISON(R) random- access chemiluminescent analyzer in hospitals and clinical reference laboratories nationwide. Testing for 25-hydroxy Vitamin D and PTH provides the physician with definitive analysis of nutritional Vitamin D deficiency, an acute concern in the elderly and in individuals with dark complexions.
"We are proud to be the leader in bone and mineral diagnostics with the introduction of DiaSorin's third generation of 25-hydroxyvitamin D testing, a LIAISON(R) chemiluminescence assay," said Stephen P. Gouze, President and General Manager of DiaSorin Inc. "LIAISON(R) offers the only antibody-based Vitamin D assay available in an automated, random access chemiluminescence platform, providing the same consistent results physicians have seen from DiaSorin's radioimmunoassay for over a decade. Patients benefit from the rapid results (35 minutes to first result) and world class-assay reliability of the LIAISON(R) system. Laboratories benefit from high throughput (180 tests per hour) and complete walk-away automation from extraction through data output."
Over 800 LIAISON(R) systems are in use worldwide with a menu of over 50 diagnostic tests including hepatitis, infectious disease and autoimmune assays. DiaSorin will be adding these and other assays in the United States as FDA clearance is received.
DiaSorin has a worldwide workforce of over 500 employees with corporate headquarters in Saluggia, Italy. U.S. operations, located in Stillwater, Minnesota, include research and development, sales, and ISO 9001-registered manufacturing facilities.
CONTACT: Rebecca Aistrup, Director of Marketing of DiaSorin Inc.,+1-651-351-5735